For the quarter ending 2025-09-30, NVNO had -$210K decrease in cash & cash equivalents over the period. -$12,130K in free cash flow.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -15,736 |
| Stock-based compensation | 2,783 |
| Depreciation and amortization | 105 |
| Amortization of right-of-use assets | 267 |
| Unrealized (gain) loss from investments | -312 |
| Prepaid expenses and other current assets | -34 |
| Accounts payable, accrued expenses and other current liabilities | 383 |
| Operating lease liabilities | -273 |
| Net cash used in operating activities | -12,125 |
| Maturities of investments | 38,381 |
| Purchase of property and equipment | 5 |
| Purchases of investments | 26,702 |
| Net cash provided by investing activities | 11,674 |
| Proceeds from warrant exercises | 241 |
| Net cash provided by financing activities | 241 |
| Net increase (decrease) in cash and cash equivalents | -210 |
| Cash and cash equivalents at beginning of period | 1,754 |
| Cash and cash equivalents at end of period | 1,544 |
enVVeno Medical Corp (NVNO)
enVVeno Medical Corp (NVNO)